Replies to post #165254 on Biotech Values

[genisi]

In order for that sales level to be attained, GSK will have to promote the use of Tivacay with Truvada rather than with GSK’s own Epzicom.

Seems that GSK by developing its own single tablet regimen (572-Trii) containing Tivacay and Epzicom is aiming to compete with Stribild, although I agree - abacavir is a big disadvantage.